FIELD: medicine.
SUBSTANCE: group of inventions discloses a composition for treating a disease or pathological condition in a subject treatable by administration of T-cells, where the composition contains isolated T-cells and where the isolated T-cells contain an introduced nucleic acid for c-Jun overexpression. Also a method of treating a disease or condition in a subject, comprising administering to a subject having a disease or condition an effective amount of a composition wherein the disease or condition is treatable by administering T-cells is disclosed.
EFFECT: technical result of the group of inventions is to reduce the depletion of isolated T-cells.
31 cl, 2 tbl, 33 dwg, 33 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENIC RECEPTORS TO CD22 | 2012 |
|
RU2644243C2 |
| MODIFIED MONOCYTES/MACROPHAGES EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2766690C2 |
| M971 CHIMERIC ANTIGEN RECEPTORS | 2013 |
|
RU2658485C2 |
| IMPROVED IMMUNE CELLS WITH DOUBLE shRNA AND COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2793922C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| MATERIALS AND METHODS FOR CANCER TREATMENT | 2019 |
|
RU2787828C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF | 2015 |
|
RU2743657C2 |
